Terminated PHASE2 INTERVENTIONAL NCT00183976

Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

A Pilot Phase II Study of Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas

Sponsor: University of Southern California

Conditions Burkitt Lymphoma Non-Hodgkin's Lymphoma Primary Effusion Lymphomas

Interventions Pegylated Liposomal Doxorubicin (Doxil) and Rituximab

Updated 5 times since 2017 Last updated: May 20, 2014 Started: Apr 30, 2005 Primary completion: Sep 30, 2005 Completion: Jan 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Insufficient Accrual

Other terminated trials from University of Southern California

See all terminations from University of Southern California

Other Burkitt Lymphoma trials with similar outcome

NCT03864419 · Phase PHASE1 · Jul 2023

Browse all Burkitt Lymphoma trials

A PHASE2 clinical study on Burkitt Lymphoma and Non-Hodgkin's Lymphoma, this trial is terminated or withdrawn. The trial is conducted by University of Southern California and has accumulated 5 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Apr 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Southern California

Data source: University of Southern California

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States